These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 2182424)

  • 21. Mitoxantrone, cytosine arabinoside, and VP-16 in 36 patients with relapsed and refractory acute myeloid leukemia.
    Link H; Freund M; Diedrich H; Wilke H; Austein J; Henke M; Wandt H; Fackler-Schwalbe E; Schlimok G; Hoffmann R
    Haematol Blood Transfus; 1990; 33():322-5. PubMed ID: 2182426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Volger WR; Weiner RS; Moore JO; Omura GA; Bartolucci AA; Stagg M
    Leukemia; 1995 Sep; 9(9):1456-60. PubMed ID: 7544851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy of childhood acute nonlymphocytic leukemia: the Pediatric Oncology Group experience (1977-1988).
    Steuber CP; Culbert SJ; Ravindranath Y; Krischer J; Ragab A; Civin C; Inoue S; Ruymann F; Leventhal B; Wilkinson R
    Haematol Blood Transfus; 1990; 33():198-209. PubMed ID: 2182412
    [No Abstract]   [Full Text] [Related]  

  • 24. Intensive consolidation chemotherapy for newly diagnosed acute myeloid leukemia using a regime containing moderate dose cytosine arabinoside and mitoxantrone.
    Liang R; Chan TK; Chu YC; Chan J; Chan CH; Chiu E; Lie A; Kwong YL; Yeung YM; Chan LC
    Anticancer Drugs; 1995 Apr; 6(2):224-8. PubMed ID: 7795271
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Short-term intensive treatment for acute myelogenous leukemia (excluding M3 subtype) in adults].
    Ino T; Yamaguchi T; Tsuzuki M; Nomura T; Miyazaki H; Maruyama F; Kojima H; Okamoto M; Matsui T; Ezaki K; Hirano M
    Rinsho Ketsueki; 1997 Mar; 38(3):209-16. PubMed ID: 9095660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Induction and intensive combined therapy of acute myeloid leukemia in adults].
    Kurrle E; Ehninger G; Freund M; Heil G; Hoelzer D; Link H; Mitrou PS; Ohl S; Queisser W; Schlimok G
    Onkologie; 1988 Feb; 11(1):5-9. PubMed ID: 3283626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction therapy for acute myelogenous leukemia in patients over 60 years with intermediate-dose cytosine arabinoside, mitoxantrone and etoposide.
    Shepherd JD; Reece DE; Barnett MJ; Klingemann HG; Nantel SH; Sutherland HJ; Phillips GL
    Leuk Lymphoma; 1993 Feb; 9(3):211-5. PubMed ID: 8471979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study Group.
    Lazarus HM; Vogler WR; Burns CP; Winton EF
    Cancer; 1989 Mar; 63(6):1055-9. PubMed ID: 2917307
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
    Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapy of acute myelogenous leukemia in adults.
    Petti MC; Broccia G; Caronia F; Di Raimondo F; Fioritoni G; Ladogana S; Leone G; Liso V; Musso M; Neri A
    Haematol Blood Transfus; 1990; 33():249-53. PubMed ID: 2182417
    [No Abstract]   [Full Text] [Related]  

  • 31. [Five cases of de novo acute myeloid leukemia with trilineage myelodysplasia (AML/TMDS) achieved CR with the continuous drip infusion of low-dose etoposide and low-dose cytosine arabinoside combined with mitoxantrone (MEtA)].
    Tsukaguchi M; Furukawa Y; Shibano M; Kitani T
    Gan To Kagaku Ryoho; 2004 Jul; 31(7):1119-23. PubMed ID: 15272598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adult AML: the role of chemotherapy intensity and duration. Two studies of the AML Cooperative Group.
    Büchner T; Hiddemann W; Blasius S; Koch P; Maschmeyer G; Tirier C; Sodomann H; Kuse R; Thiel E; Ludwig WD
    Haematol Blood Transfus; 1990; 33():261-6. PubMed ID: 2182419
    [No Abstract]   [Full Text] [Related]  

  • 33. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment.
    Maschmeyer G; Willborn K; Heit W
    Leuk Lymphoma; 1992 Nov; 8(4-5):365-9. PubMed ID: 1290961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-remission therapy of adult acute myeloid leukemia: high dose cytosine-arabinoside versus other consolidation regimens.
    Zeremski V; Savić A
    Med Pregl; 2014; 67(3-4):83-90. PubMed ID: 24961049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive models for achievement of complete remission and duration of first remission in adult acute myeloid leukemia.
    Heinecke A; Sauerland MC; Büchner T
    Haematol Blood Transfus; 1990; 33():285-9. PubMed ID: 2182422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.
    Harousseau JL; Milpied N; Briere J; Desablens B; Le Prise PY; Ifrah N; Gandhour C; Casassus P
    Haematol Blood Transfus; 1990; 33():299-303. PubMed ID: 2323633
    [No Abstract]   [Full Text] [Related]  

  • 38. [Complications associated with short-term intensive consolidation chemotherapy for adults with acute myelogenous leukemia].
    Nagata K; Abe Y; Hatanaka T; Ito T; Saito M; Ono Y; Kamiya O; Ohara K
    Gan To Kagaku Ryoho; 1993 Sep; 20(12):1869-72. PubMed ID: 8379681
    [No Abstract]   [Full Text] [Related]  

  • 39. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
    Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
    Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
    Schaich M; Parmentier S; Kramer M; Illmer T; Stölzel F; Röllig C; Thiede C; Hänel M; Schäfer-Eckart K; Aulitzky W; Einsele H; Ho AD; Serve H; Berdel WE; Mayer J; Schmitz N; Krause SW; Neubauer A; Baldus CD; Schetelig J; Bornhäuser M; Ehninger G
    J Clin Oncol; 2013 Jun; 31(17):2094-102. PubMed ID: 23630210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.